Quarry LP acquired a new stake in shares of Inari Medical, Inc. (NASDAQ:NARI – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 1,115 shares of the company’s stock, valued at approximately $57,000.
A number of other institutional investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in shares of Inari Medical by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 5,628,875 shares of the company’s stock worth $287,354,000 after purchasing an additional 30,702 shares during the last quarter. Jennison Associates LLC boosted its holdings in Inari Medical by 11.8% in the fourth quarter. Jennison Associates LLC now owns 1,763,258 shares of the company’s stock worth $90,014,000 after purchasing an additional 186,617 shares in the last quarter. American Century Companies Inc. boosted its holdings in Inari Medical by 9.1% in the fourth quarter. American Century Companies Inc. now owns 1,068,487 shares of the company’s stock worth $54,546,000 after purchasing an additional 89,108 shares in the last quarter. Fuller & Thaler Asset Management Inc. increased its position in Inari Medical by 13.3% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 870,633 shares of the company’s stock worth $44,446,000 after buying an additional 102,111 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in Inari Medical by 6.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 701,435 shares of the company’s stock valued at $35,810,000 after buying an additional 43,475 shares in the last quarter. 90.98% of the stock is currently owned by institutional investors and hedge funds.
Inari Medical Stock Performance
NASDAQ:NARI opened at $79.97 on Friday. The firm’s 50-day moving average is $79.97 and its 200-day moving average is $67.85. The company has a market cap of $4.68 billion, a price-to-earnings ratio of -59.24 and a beta of 1.02. Inari Medical, Inc. has a 52-week low of $39.76 and a 52-week high of $79.99.
Analyst Ratings Changes
Inari Medical Profile
Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.
Further Reading
- Five stocks we like better than Inari Medical
- What Are Treasury Bonds?
- The Most Inspiring Small Businesses of 2025 [Survey]
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Microsoft Crushes Earnings, What’s Next for MSFT Stock?
- How to Short a Stock in 5 Easy Steps
- McDonald’s Insiders Sell Shares! Investors Should Do the Opposite
Want to see what other hedge funds are holding NARI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inari Medical, Inc. (NASDAQ:NARI – Free Report).
Receive News & Ratings for Inari Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inari Medical and related companies with MarketBeat.com's FREE daily email newsletter.